Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Epsins 1 and 2 promote NEMO linear ubiquitination via LUBAC to drive breast cancer development
Kai Song, … , Yibin Kang, Hong Chen
Kai Song, … , Yibin Kang, Hong Chen
Published September 22, 2020
Citation Information: J Clin Invest. 2021;131(1):e129374. https://doi.org/10.1172/JCI129374.
View: Text | PDF
Research Article Cell biology Oncology

Epsins 1 and 2 promote NEMO linear ubiquitination via LUBAC to drive breast cancer development

  • Text
  • PDF
Abstract

Estrogen receptor–negative (ER-negative) breast cancer is thought to be more malignant and devastating than ER-positive breast cancer. ER-negative breast cancer exhibits elevated NF-κB activity, but how this abnormally high NF-κB activity is maintained is poorly understood. The importance of linear ubiquitination, which is generated by the linear ubiquitin chain assembly complex (LUBAC), is increasingly appreciated in NF-κB signaling, which regulates cell activation and death. Here, we showed that epsin proteins, a family of ubiquitin-binding endocytic adaptors, interacted with LUBAC via its ubiquitin-interacting motif and bound LUBAC’s bona fide substrate NEMO via its N-terminal homolog (ENTH) domain. Furthermore, epsins promoted NF-κB essential modulator (NEMO) linear ubiquitination and served as scaffolds for recruiting other components of the IκB kinase (IKK) complex, resulting in the heightened IKK activation and sustained NF-κB signaling essential for the development of ER-negative breast cancer. Heightened epsin levels in ER-negative human breast cancer are associated with poor relapse-free survival. We showed that transgenic and pharmacological approaches eliminating epsins potently impeded breast cancer development in both spontaneous and patient-derived xenograft breast cancer mouse models. Our findings established the pivotal role epsins played in promoting breast cancer. Thus, targeting epsins may represent a strategy to restrain NF-κB signaling and provide an important perspective into ER-negative breast cancer treatment.

Authors

Kai Song, Xiaofeng Cai, Yunzhou Dong, Hao Wu, Yong Wei, Uma T. Shankavaram, Kui Cui, Yang Lee, Bo Zhu, Sudarshan Bhattacharjee, Beibei Wang, Kun Zhang, Aiyun Wen, Scott Wong, Lili Yu, Lijun Xia, Alana L. Welm, Diane R. Bielenberg, Kevin A. Camphausen, Yibin Kang, Hong Chen

×

Figure 4

The interaction of epsin with LUBAC is critical for NF-κB activation.

Options: View larger image (or click on image) Download as PowerPoint
The interaction of epsin with LUBAC is critical for NF-κB activation.
(A...
(A) Ctrl MDA231 cells (generated by transfecting scrambled siRNAs using lipofectamine RNAiMAX) or epsin 1 and 2 KD MDA231 cells (generated by transfecting siRNAs against epsin 1 and epsin 2, respectively) were stimulated with human TNF-α (hTNF-α; 50 ng/mL) for the indicated time, lysed, and pulled down with epsin 1 antibody at 4°C for 4 hours, followed by Western blot analysis of epsin 1, HOIP, HOIL-1L, and NEMO. (B) Western blot analysis of mouse TNF-α–induced (mTNF-α–induced) phosphorylation of p65, IκB-α, IKK-β/α, JNK, and p38 in WT and DKO mouse primary fibroblasts. Both groups were treated with 50 ng/mL mTNF-α for the indicated time. (C) Western blot analysis of mTNF-α–induced (50 ng/mL, final concentration, 5 minutes) phosphorylation of p65, IκB-α, or IKK-β in WT and DKO mouse primary fibroblasts, with or without overexpression of Flag-tagged HOIP and Flag-tagged HOIL-1L. Results are representative of 3 independent experiments (A–C).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts